UCLA - Satellite Site
Welcome,         Profile    Billing    Logout  
 0 Trials 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vachhani, Pankit
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
330
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
HARBOR, NCT04910685 / 2020-005173-28: () Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Recruiting
2/3
463
Europe, US, RoW
Elenestinib, BLU-263, Placebo
Blueprint Medicines Corporation
Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis
06/28
06/28
NCI-2019-08626, NCT04214249: BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Active, not recruiting
2
50
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Echocardiography, EC, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Infusion, HEMATOPOIETIC STEM CELL TRANSPLANT, Hematopoietic Stem Cell Transplantation, HSCT, SCT, Stem Cell Transplant, stem cell transplantation, Stem Cell Transplantation, NOS, Idarubicin Hydrochloride, Idamycin, Idamycin PFS, Idarubicin HCl, IMI-30, SC-33428, Zavedos, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Punch Biopsy, BIOPSY, PUNCH, Punch Biopsy of Skin
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
07/25
07/25
NCT04975555: Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Recruiting
2
30
US
Siltuximab
University of Alabama at Birmingham
Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
12/26
12/27
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
ZN-d5-004C, NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Hourglass Jul 2024 - Dec 2024 : Preliminary data r/r/ AML
Terminated
1/2
40
US
ZN-d5 ZN-c3, Study Drug, ZN-c3
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Acute Myeloid Leukemia (AML)
07/24
07/24
NCT05886491: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
53
US
GDX012, Chemotherapy Agents
Takeda
Leukemia
04/26
06/27
SGNS70-101, NCT04227847: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Recruiting
1
140
Europe, US
SEA-CD70, azacitidine, VIDAZA
Seagen Inc.
Myelodysplastic Syndrome, Acute Myeloid Leukemia
12/24
11/26
NCT04167917: NTX-301 in MDS/AML

Recruiting
1
20
US
NTX-301
University of Alabama at Birmingham
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
12/27
03/28

Download Options